Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation
Clinical Lung Cancer2020Vol. 21(4), pp. e258–e260
Citations Over TimeTop 10% of 2020 papers
Related Papers
- → Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells(2018)14 cited
- → The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC(2021)6 cited
- → Abstract 2113:KRASamplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR(2019)
- → EP1.14-10 Investigation of Mechanisms of Acquired Resistance to Afatinib with Plasma DNA in Non-Small Cell Lung Cancer Patients(2019)
- → Abstract 2113: KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR(2019)